PT  - JOURNAL ARTICLE
AU  - Ashton, Philip M.
AU  - Chirambo, Angeziwa Chunga
AU  - Meiring, James E.
AU  - Patel, Priyanka D.
AU  - Mbewe, Maurice
AU  - Silungwe, Niza
AU  - Chizani, Kenneth
AU  - Banda, Happy
AU  - Heyderman, Robert S.
AU  - Dyson, Zoe A.
AU  - MacPherson, Peter
AU  - Henrion, Marc Y.R.
AU  - ,
AU  - Holt, Kathryn E.
AU  - Gordon, Melita A.
TI  - The rapid emergence of <em>Salmonella</em> Typhi with decreased ciprofloxacin susceptibility following an increase in ciprofloxacin prescriptions in Blantyre, Malawi
AID  - 10.1101/2023.03.27.23287794
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.27.23287794
4099  - http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287794.short
4100  - http://medrxiv.org/content/early/2023/03/29/2023.03.27.23287794.full
AB  - Ciprofloxacin is the first-line drug for treating typhoid fever in many high burden countries in Africa, but the emergence of non-susceptibility poses a grave challenge to public health programmes. Through enhanced surveillance as part of vaccine evaluation, we set out to investigate the occurrence and determinants of ciprofloxacin non-susceptibility in Blantyre, Malawi.We performed systematic typhoid fever and antibiotic prescription surveillance in two health centres in Blantyre, Malawi between 01/10/2016 and 31/10/2019, as part of the STRATAA and TyVAC studies. Blood culture isolates from study participants underwent i) pefloxacin screening and ciprofloxacin E-tests to identify ciprofloxcain non-susceptibility and ii) whole genome sequencing (WGS) to identify drug resistance mutations and phylogenetic relationships between non-susceptible and sensitive isolates. We constructed generalised linear regression models to investigate associations between ciprofloxacin prescription rates and S. Typhi isolates with Quinolone Resistance Determining Region (QRDR) mutations.We carried out 11295 blood cultures and microbiologically confirmed 239 cases of typhoid fever, with isolates from 193 participants sequenced (mean age of participants with sequenced genomes 12.8 years, 47% male). Between October 2016 and August 2019 2% (n=4/175) of WGS-confirmed typhoid fever cases were caused by S. Typhi with QRDR mutations, compared with 33% (n=6/18) in September and October 2019. Nine of the ten S. Typhi with QRDR mutations had a decreased ciprofloxacin susceptibility phenotype. Every additional prescription of ciprofloxacin given to study participants in the preceding month was associated with a 4.2% increase in the relative risk of isolating S. Typhi with a QRDR mutation (95% CI, 1.8-7.0%, p=0.0008). Phylogenetic analysis showed that S. Typhi isolates with QRDR mutations in September/October 2019 belonged to two distinct sub-clades encoding two different QRDR mutations, and were closely related (0-6 SNPs) to susceptible S. Typhi endemic to Blantyre.We have shown a close temporal association between empiric antimicrobial usage with an increase of fluoroquinolone non-susceptibility in S. Typhi, with two sub-clades responsible for the increase. Decreasing ciprofloxacin usage by improving typhoid diagnostics could help to limit the emergence of resistance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in part by the Wellcome Trust [Grant numbers 200901/Z/16/Z to PM and 206545/Z/17/Z to MLW and supporting, in part, MYRH and 106158/Z/14/Z to the STRATAA Consortium]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This work was supported by grants (OPP1151153, to the Typhoid Vaccine Acceleration Consortium and OPP1141321 to the STRATAA Consortium) from the Bill and Melinda Gates Foundation. MAG, ACC and PMA were supported by a Research Professorship (NIHR300039) from the National Institute for Health Research, U.K. Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University of Liverpool gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPhylogenetic trees and annotation files are available from FigShare at the following link https://figshare.com/projects/Fluoroquinolone_resistance_Salmonella_Typhi_in_Blantyre_Malawi/157785. Code to reproduce the statistical analysis and generate the plots can be accessed from https://github.com/flashton2003/blantyre_qrdr_typhi. Genome accessions are available in Supplementary Table 1.